Molecular Predictors of Response to Therapy for Breast Cancer
作者： Natalie Galanina , Veerle Bossuyt , Lyndsay N. Harris
DOI: 10.1097/PPO.0B013E318212DEE3
关键词:
摘要: For several decades, measurements from tumor tissue biomarkers have been used to identify subsets of breast cancer patients that may benefit specific therapies. Since the 1980s, estrogen receptor testing has routinely performed on carcinoma samples determine whether hormonal therapy is indicated. Today, receptor, progesterone and human epidermal growth factor type 2 guide treatment decisions are standard care. In recent years, multigene assays introduced predict behavior. particular, OncotypeDx MammaPrint commercialized in North America Europe clinical decisions. Others, including Breast Cancer Index (BCI; bioTheranostics) PAM50 (Expression Analysis, Inc), gaining acceptance as validated with associated outcomes. addition, certain germ line genetic tests now reported response treatments (e.g., BRCA1, 2, CYP2D6). The optimal use these novel molecular a challenge practicing oncologist. this review, we will focus role provide framework for oncologists understand evaluate tools practice.
lww.com
sci-hub.se 参考文章(63)
Lyndsay Harris, Herbert Fritsche, Robert Mennel, Larry Norton, Peter Ravdin, Sheila Taube, Mark R. Somerfield, Daniel F. Hayes, Robert C. Bast, American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer Journal of Clinical Oncology. ,vol. 25, pp. 5287- 5312 ,(2007) , 10.1200/JCO.2007.14.2364
Yun Gong, Kai Yan, Feng Lin, Keith Anderson, Christos Sotiriou, Fabrice Andre, Frankie A Holmes, Vicente Valero, Daniel Booser, John E Pippen, Svetislava Vukelja, Henry Gomez, Jaime Mejia, Luis J Barajas, Kenneth R Hess, Nour Sneige, Gabriel N Hortobagyi, Lajos Pusztai, W Fraser Symmans, None, Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study Lancet Oncology. ,vol. 8, pp. 203- 211 ,(2007) , 10.1016/S1470-2045(07)70042-6
Christos Sotiriou, Pratyaksha Wirapati, Sherene Loi, Adrian Harris, Steve Fox, Johanna Smeds, Hans Nordgren, Pierre Farmer, Viviane Praz, Benjamin Haibe-Kains, Christine Desmedt, Denis Larsimont, Fatima Cardoso, Hans Peterse, Dimitry Nuyten, Marc Buyse, Marc J Van de Vijver, Jonas Bergh, Martine Piccart, Mauro Delorenzi, None, Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis Journal of the National Cancer Institute. ,vol. 98, pp. 262- 272 ,(2006) , 10.1093/JNCI/DJJ052
Xiao-Jun Ma, Zuncai Wang, Paula D Ryan, Steven J Isakoff, Anne Barmettler, Andrew Fuller, Beth Muir, Gayatry Mohapatra, Ranelle Salunga, J.Todd Tuggle, Yen Tran, Diem Tran, Ana Tassin, Paul Amon, Wilson Wang, Wei Wang, Edward Enright, Kimberly Stecker, Eden Estepa-Sabal, Barbara Smith, Jerry Younger, Ulysses Balis, James Michaelson, Atul Bhan, Karleen Habin, Thomas M Baer, Joan Brugge, Daniel A Haber, Mark G Erlander, Dennis C Sgroi, A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell. ,vol. 5, pp. 607- 616 ,(2004) , 10.1016/J.CCR.2004.05.015
Fergus J. Couch, Matthew P. Goetz, Vera J. Suman, James N. Ingle, Andrea M. Nibbe, Dan W. Visscher, Carol A. Reynolds, Wilma L. Lingle, Mark Erlander, Xiao-Jun Ma, Dennis C. Sgroi, Edith A. Perez, A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen Clinical Cancer Research. ,vol. 12, pp. 2080- 2087 ,(2006) , 10.1158/1078-0432.CCR-05-1263
Laura J. van 't Veer, Hongyue Dai, Marc J. van de Vijver, Yudong D. He, Augustinus A. M. Hart, Mao Mao, Hans L. Peterse, Karin van der Kooy, Matthew J. Marton, Anke T. Witteveen, George J. Schreiber, Ron M. Kerkhoven, Chris Roberts, Peter S. Linsley, René Bernards, Stephen H. Friend, Gene expression profiling predicts clinical outcome of breast cancer Nature. ,vol. 415, pp. 530- 536 ,(2002) , 10.1038/415530A
T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. E. Lonning, A.-L. Borresen-Dale, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proceedings of the National Academy of Sciences of the United States of America. ,vol. 98, pp. 10869- 10874 ,(2001) , 10.1073/PNAS.191367098
Joel S. Parker, Michael Mullins, Maggie C.U. Cheang, Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu, John F. Quackenbush, Inge J. Stijleman, Juan Palazzo, J.S. Marron, Andrew B. Nobel, Elaine Mardis, Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. Bernard, Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes Journal of Clinical Oncology. ,vol. 27, pp. 1160- 1167 ,(2009) , 10.1200/JCO.2008.18.1370
Clifford A. Hudis, Trastuzumab — Mechanism of Action and Use in Clinical Practice The New England Journal of Medicine. ,vol. 357, pp. 39- 51 ,(2007) , 10.1056/NEJMRA043186
B. Sirohi, M. Arnedos, S. Popat, S. Ashley, A. Nerurkar, G. Walsh, S. Johnston, I.E. Smith, Platinum-based chemotherapy in triple-negative breast cancer Annals of Oncology. ,vol. 19, pp. 1847- 1852 ,(2008) , 10.1093/ANNONC/MDN395